A rare case? Or a blind spot? Hair loss caused by low T + e2 Chat 6/1/2025
Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Estradiol (E2), Testosterone and DHT levels after 1 month on Dutasteride
Dutasteride and finasteride are used for hair loss, affecting hormone levels like DHT and testosterone. Hormone balance is crucial, as changes can lead to side effects such as increased estradiol and potential hair loss.
community Topical finasteride has affected my hormones
A 21-year-old experienced hormone changes after using self-made topical finasteride for hair loss, including a 20% decrease in DHT, a 47% increase in testosterone, and a 39% increase in estradiol. The user previously used minoxidil and microneedling but is now seeking ways to balance hormones, possibly through supplements or dosage adjustments.
community My hormone levels after 2 months of Finasteride and 2 weeks of Dutasteride
The conversation discusses elevated hormone levels after using Finasteride for 2 months and Dutasteride for 2 weeks for hair loss. Users suggest that increased testosterone and estradiol levels are expected due to DHT inhibition, and it's not a concern unless symptoms occur.
community Can you take something like Spiro or even Estradiol if already on low dose TRT to regrow hair?
The conversation discusses using treatments like dutasteride, minoxidil, spironolactone, and estradiol for hair regrowth while maintaining muscle mass. Concerns include potential side effects like gynecomastia and muscle loss, with suggestions to balance hormone levels carefully.
community Testosterone and hair loss seeming irrelevance
The conversation is about the role of testosterone in hair loss and the effectiveness of different treatments. The conclusion is that DHT is the main culprit for hair loss, and finasteride has been proven to work long-term in maintaining and regrowing hair. Testosterone may have a minor effect, but it is not the primary cause of hair loss.
Related Research
6 / 6 resultsresearch Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women
This study found that prolonged use of finasteride in women led to altered levels of sex steroids, DNA damage, and increased menstrual bleeding, suggesting adverse health effects without clear benefits for androgenetic alopecia treatment.
research Biochemical Roles of Testosterone and Epitestosterone to 5α-Reductase as Indicators of Male-Pattern Baldness
High testosterone to epitestosterone ratio in hair could predict male-pattern baldness.
research The Hormonal Background of Hair Loss in Non-Scarring Alopecias
This review examines the hormonal causes of hair loss, noting how androgen excess can lead to follicle miniaturization and linking estrogen deficiency and thyroid dysfunction to common alopecia types. It further discusses hormonal treatments such as finasteride, dutasteride, and spironolactone.
research Moxibustion improves ovarian function based on the regulation of the androgen balance
This study suggested that moxibustion treatment before or at the early stage of diminished ovarian reserve in rats may improve ovarian function by modulating androgen balance, though its effects differ across intervention timings.
research Short‐ and Long‐Term Clinical Skin Effects of Testosterone Treatment in Trans Men
This study found that testosterone therapy in trans men increased facial and body hair growth while the prevalence and severity of acne peaked at 6 months but were primarily mild after long-term treatment.
research Gender Differences in Production and Circulating Levels of Sex Hormones and Their Impact on Aging Skin
This review discusses how sex hormone levels and local steroid synthesis influence gender differences in aging skin, reporting no new clinical results.